3,277
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Current approaches to evaluate the function of cytotoxic T-cells in non-human primates

, , , , , , , , , , & show all
Article: 2176952 | Received 19 Oct 2022, Accepted 01 Feb 2023, Published online: 14 Feb 2023

References

  • Andersen M, Schrama D, Thor Straten P, Becker J. 2006. Cytotoxic T-cells. J Invest Dermatol. 126(1):32–41.
  • Betts M, Brenchley J, Price D, De Rosa S, Douek D, Roederer M, Koup R. 2003. Sensitive and viable identification of antigen-specific CD8+ T-cells by a flow cytometric assay for degranu-lation. J Immunol Meth. 281:65–78.
  • Brunner K, Mauel J, Cerottini J, Chapuis B. 1968. Quantitative assay of the lytic action of immune lymphoid cells on 51Cr-labeled allogeneic target cells in vitro: Inhibition by isoantibody and by drugs. Immunology. 14:181–196.
  • Budde M, Greene J, Chin E, Ericsen A, Scarlotta M, Cain B, Pham N, Becker E, Harris M, Weinfurter J, et al. 2012. Specific CD8+ T-cell responses correlate with control of simian immunodeficiency virus replication in Mauritian cynomolgus macaques. J Virol. 86(14):7596–7604.
  • Budde ML, Lhost JJ, Burwitz BJ, Becker EA, Burns CM, O'Connor SL, Karl JA, Wiseman RW, Bimber BN, Zhang GL, et al. 2011. Transcriptionally-abundant major histocompatibility complex class I alleles are fundamental to non-human primate simian immunodeficiency virus-specific CD8+ T-cell responses. J Virol. 85(7):3250–3261.
  • Carson C, Antoniou M, Ruiz-Argüello M, Alcami A, Christodoulou V, Messaritakis I, Blackwell J, Courtenay O. 2009. A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis. Vaccine. 27(7):1080–1086.
  • Carvalho L, Hafalla J, Zavala F. 2001. ELISPOT assay to measure antigen-specific murine CD8+ T-cell responses. J Immunol Meth. 252:207–218.
  • Carville A, Mansfield K. 2008. Comparative pathobiology of macaque lymphocryptoviruses. Compar Med. 58:57–67.
  • Cassaniti I, Cavagna L, Calarota SA, Adzasehoun KMG, Comolli G, Montecucco C, Baldanti F. 2019. Evaluation of EBV- and HCMV-Specific T cell Responses in Systemic Lupus Erythematosis (SLE) Patients Using a Normalized Enzyme-Linked Immunospot (ELISPOT) Assay. J Immunol Res. 2019:1–12.
  • Cassioli C, Baldari C. 2022. The expanding arsenal of cytotoxic T-cells. Front Immunol. 13:883010.
  • Domi A, Feldmann F, Basu R, McCurley N, Shifflett K, Emanuel J, Hellerstein M, Guirakhoo F, Orlandi C, Flinko R, et al. 2018. a single dose of modified vaccinia Ankara expressing Ebola virus-like particles protects non-human primates from lethal Ebola virus challenge. Sci Rep. 8(1):864.
  • Frank B, Guo H, Lebrec H, Wang X. 2021. Application of a newly-developed cynomolgus macaque BiTE-mediated cytotoxic T-lymphocyte activity assay to various immunomodula-tory agents in vitro. J Immunotoxicol. 18:154–162.
  • Frank B, Wei Y, Kim K, Guerrero A, Lebrec H, Balazs M, Wang X. 2018. Development of a BiTE®-mediated CD8+ cytotoxic T-lymphocyte activity assay to assess immunomodulatory potential of drug candidates in cynomolgus macaque. J Immunotoxicol. 15(1):119–125.
  • Freundt-Revilla J, Maiolini A, Carlson R, Beyerbach M, Rentmeister K, Flegel T, Fischer A, Tipold A. 2017. TH17-skewed immune response and cluster of differentiation 40 ligand expression in canine steroid-responsive meningitis-arteritis, a large animal model for neutrophilic meningitis. J Neuroinflamm. 14(20):13p. DOI 10.1186/s12974-016-0784-3
  • Graveline R, Haida M, Dumont C, Poulin D, Poitout-Belissent F, Samadfam R, Kronenberg S, Regenass-Lechner F, Prell R, Piche M. 2022. Development of a non-human primate challenge model to evaluate CD8+ T-cell responses to an adenovirus-based vaccine expres-sing SIV proteins upon repeat-dose treatment with checkpoint inhibitors. MAbs. 14(1):1979447.
  • Habis A, Baskin G, Simpson L, Fortgang I, Murphey-Corb M, Levy L. 2000. Rhesus Lymphocryptovirus Infection during the progression of SAIDS and SAIDS-associated lymphoma in the rhesus macaque. AIDS Res Hum Retroviruses. 16(2):163–171.
  • Horton H, Russell N, Moore E, Frank I, Baydo R, Daughton C, Lee D, Deers M, Hudgens M, Weinhold K, et al. 2004. Correlation between IFNγ secretion and cytotoxicity, in virus-specific memory T-cells. J Infect Dis. 190(9):1692–1696.
  • ICH-International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. 2005. ICH harmonised tripartite guideline – immunotoxicity studies for human pharmaceuticals S8. [Online]. [accessed 2022 Mar 10]. https://database.ich.org/sites/default/files/S8_Guideline_0.pdf.
  • Itell H, Kaur A, Deere J, Barry P, Permar S. 2017. Rhesus monkeys for a non-human primate model of cytomegalovirus infections. Curr Opin Virol. 25:126–133.
  • Janetzki S, Price L, Schroeder H, Britten C, Welters M, Hoos A. 2015. Guidelines for the automated evaluation of ELISPOT assays. Nat Protoc. 10(7):1098–1115.
  • Kamperschroer C, Gosink MM, Kumpf SW, O'Donnell LM, Tartaro KR. 2016. The genomic sequence of lymphocryptovirus from cynomolgus macaque. Virology. 488:28–36.
  • Kamperschroer C, O'Donnell LM, Schneider PA, Li D, Roy M, Coskran TM, Kawabata TT. 2014. Measuring T-cell responses against LCV and CMV in cynomolgus macaques using ELISPOT: Potential application to non-clinical testing of immunomodulatory therapeutics. J Immunotoxicol. 11(1):35–43.
  • Kamperschroer C, Tartaro K, Kumpf S. 2014. Quantitative PCR assays reveal high prevalence of lymphocryptovirus as well as lytic phase gene expression in peripheral blood cells of cynomolgus macaques. J Virol Methods. 207:220–225.
  • Kawabata T, Weaver J, Thomas D, Rowe M, Wang F, Kamperschroer C, Haggerty H. 2012. Summary of roundtable discussion meeting: Non-human primates to assess risk for EBV-related lymphomas in humans. J Immunotoxicol. 9(1):121–127.
  • Kutok J, Klumpp S, Simon M, MacKey J, Nguyen V, Middeldorp J, Aster J, Wang F. 2004. Molecular evidence for rhesus lymphocryptovirus infection of epithelial cells in immunosuppressed rhesus macaques. J Virol. 78(7):3455–3461.
  • Lebrec H, Brennan F, Haggerty H, Herzyk D, Kamperschroer C, Maier C, Ponce R, Preston B, Weinstock D, Mellon R. 2016. HESI/FDA workshop on immunomodulators and cancer risk assessment: Building blocks for a weight-of-evidence approach. Regul Toxicol Pharmacol. 75:72–80.
  • Lopera-Madrid J, Osorio JE, He Y, Xiang Z, Adams LG, Laughlin RC, Mwangi W, Subramanya S, Neilan J, Brake D, et al. 2017. Safety and immunogenicity of mammalian cell-derived and modified Vaccinia Ankara-vectored African swine fever subunit antigens in swine. Vet Immunol Immunopathol. 185:20–33.
  • Mäkitalo B, Andersson M, Areström I, Karlén K, Villinger F, Ansari A, Paulie S, Thorstensson R, Ahlborg N. 2002. ELISpot and ELISA analysis of spontaneous, mitogen-induced, and antigen-specific cytokine production in cynomolgus and rhesus macaques. J Immunol Meth. 270:85–97.
  • Megyesi Z, Lehmann P, Karulin A. 2018. Multi-color FLUOROSPOT counting using ImmunoSpot® Fluoro-X™ Suite. Meth Mol Biol. 1808:115–131.
  • Moldovan I, Brewoo J, Osorio J, Tary-Lehmann M. 2011. Assessment of T-cell-mediated immunity by ELISPOT in preclinical studies of dengue in cynomolgus macaques (106.6). J Immunology. 186(S1):106.6.
  • Mühe J, Wang F. 2015. Non-human primate lymphocryptoviruses: Past, present, and future. Curr Topics Microbiol Immunol. 391:385–405.
  • O'Hara D, Xu Y, Liang Z, Reddy M, Wu D, Litwin V. 2011. Recommendations for the validation of flow cytometric testing during drug development: II assays. J Immunol Methods. 363(2):120–134.
  • Ramírez J, Gherardi M, Esteban M. 2000. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: Virus fate and activation of B- and T-cell immune responses in comparison with the Western reserve strain and advantages as a vaccine. J Virol. 74(2):923–933.
  • Raskov H, Orhan A, Christensen J, Gögenur I. 2021. Cytotoxic CD8+ T-cells in cancer and cancer immunotherapy. Br J Cancer. 124(2):359–367.
  • Rivailler P, Carville A, Kaur A, Rao P, Quink C, Kutok JL, Westmoreland S, Klumpp S, Simon M, Aster JC, et al. 2004. Experimental rhesus lymphocryptovirus infection in immunosup-pressed macaques: An animal model for Epstein-Barr virus pathogenesis in the immuno-suppressed host. Blood. 104(5):1482–1489.
  • Schultheis K, Schaefer H, Pugh H, Yung B, Oh J, Nguyen J, Humeau L, Broderick K, Smith T. 2019. Optimized IFNγ ELISpot assay to measure T-cell responses in the guinea pig model after vaccination. J Visual Exp. 143:e58595.
  • Trapani J, Smyth M. 2002. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol. 2(10):735–747.
  • U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, & Center for Biologics Evaluation and Research. 2006. Guidance for industry – S8 immunotoxicity studies for human pharmaceuticals [Online]. [accessed 2022 Mar 10]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s8-immunotoxicity-studies-human-pharmaceuticals.
  • van der Strate B, Longdin R, Geerlings M, Bachmayer N, Cavallin M, Litwin V, Patel M, Passe-Coutrin W, Schoelch C, Companjen A, et al. 2017. Best practices in performing flow cytometry in a regulated environment: feedback from experience within the European Bioanalysis Forum. Bioanalysis. 9(16):1253–1264.
  • Weidinger G, Ohlmann M, Schlereth B, Sutter G, Niewiesk S. 2001. Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat model. Vaccine. 19:2764–2768.
  • Weinhold K, Bukowski J, Brennan T, Noveck R, Staats J, Lin L, Stempora L, Hammond C, Wouters A, Mojcik C, et al. 2018. Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers. Clin Immunol. 191:10–20.
  • Yang F, Patton K, Kasprzyk T, Long B, Gupta S, Zoog S, Tracy K, Vettermann C. 2022. Validation of an IFNγ ELISpot assay to measure cellular immune responses against viral antigens in non-human primates. Gene Therapy. 29:41–24.
  • Yue Y, Barry P. 2008. Chapter 5. Rhesus cytomegalovirus: A non-human primate model for the study of human cytomegalovirus. Vol. 72. In: Maramorosch K, Shatkin A, Murphy F, editors. Advances in virus research. New York: Academic Press; p. 207–226.
  • Zhang N, Bevan M. 2011. CD8+ T-cells: Foot soldiers of the immune system. Immunity. 35(2):161–168.
  • Zuber B, Quigley M, Critchfield J, Shacklett B, Abel K, Miller C, Mörner A, Paulie S, Ahlborg N, Sandberg J. 2006. Detection of macaque perforin expression and release by flow cyto-metry, immunohistochemistry, ELISA, and ELISpot. J Immunol Methods. 312(1–2):45–53.